As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses.
Published in 360Dx
Author: Kelsy Ketchum
Abstract:
As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses.
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing round to support its European commercialization. Outcome Capital served as the exclusive strategic and financial advisor to the company. ELIOS’ implant-free, minimally invasive Excimer Laser Trabeculostomy glaucoma procedure is approved […]
Read MoreOutcome Capital Life Science Market Pulse May 2022 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?